Association of serum vitamin D levels in Japanese patients with multiple sclerosis

Clinical and Experimental Neuroimmunology

Volumn 4, Issue 2, 2013, Pages 193-200

  Niino, Masaaki ^a   Fukazawa, Toshiyuki ^b   Miyazaki, Yusei ^a   Minami, Naoya ^a   Tashiro, Jun ^a   Amino, Itaru ^a   Nonaka, Takayuki ^a   Fujiki, Naoto ^a   Doi, Shizuki ^a   Kikuchi, Seiji ^a  

^a HOKKAIDO MEDICAL CENTER   (Japan)

^b Sapporo Neurology Clinic   (Japan)

Author keywords

multiple sclerosis; progression; severity; vitamin D; vitamin D binding protein

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; CALCITRIOL; ELDECALCITOL; PHTHALIC ACID DIBUTYL ESTER; VITAMIN D; VITAMIN D BINDING PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS SEVERITY SCORE; NORMAL HUMAN; PRIORITY JOURNAL; RISK FACTOR; VITAMIN BLOOD LEVEL; VITAMIN INTAKE;

EID: 84883373746     PISSN: None     EISSN: 17591961     Source Type: Journal    
DOI: 10.1111/cen3.12031     Document Type: Article

References (31)

1. Niino M,. Vitamin D and its immunoregulatory role in multiple sclerosis. Drugs Today (Barc). 2010; 46 (4): 279-90.
2. Cutolo M, Otsa K,. Review: vitamin D, immunity and lupus. Lupus. 2008; 17 (1): 6-10.
3. Holick MF,. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004; 79 (3): 362-71.
4. D'hooghe MB, Haentjens P, Nagels G, Garmyn M, De Keyser J,. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis. Mult Scler. 2012; 18 (4): 451-9.
5. Salzer J, Hallmans G, Nyström M, Stenlund H, Wadell G, Sundström P,. Vitamin D as a protective factor in multiple sclerosis. Neurology. 2012; 79 (21): 2140-5.
6. Daiger SP, Schanfield MS, Cavalli-Sforza LL,. Group-specific component (Gc) proteins bind vitamin D and 25-hydroxyvitamin D. Proc Natl Acad Sci USA. 1975; 72 (6): 2076-80.
7. White P, Cooke N,. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metab. 2000; 11 (8): 320-7.
8. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69 (2): 292-302.
9. Lublin FD, Reingold SC,. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996; 46 (4): 907-11.
10. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG,. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66 (10): 1485-9.
11. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG,. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6 (9): 805-15.
12. Kurtzke JF,. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33 (11): 1444-52.
13. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005; 64 (7): 1144-51.
14. Armas LA, Dowell S, Akhter M, Duthuluru S, Huerter C, Hollis BW, et al. Ultraviolet-B radiation increases serum 25-hydroxyvitamin D levels: the effect of UVB dose and skin color. J Am Acad Dermatol. 2007; 57 (4): 588-93.
15. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A,. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006; 296 (23): 2832-8.
16. Gelfand JM, Cree BA, McElroy J, Oksenberg J, Green R, Mowry EM, et al. Neurology. Vitamin D in African Americans with multiple sclerosis. Neurology. 2011; 76 (21): 1824-30.
17. Kampman MT, Wilsgaard T, Mellgren SI,. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol. 2007; 254 (4): 471-7.
18. Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM,. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther. 2008; 324 (1): 23-33.
19. Shinpo K, Kikuchi S, Sasaki H, Moriwaka F, Tashiro K,. Effect of 1,25-dihydroxyvitamin D(3) on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by L-buthionine sulfoximine and 1-methyl-4- phenylpyridine. J Neurosci Res. 2000; 62 (3): 374-82.
20. McDowell TY, Amr S, Culpepper WJ, Langenberg P, Royal W, Bever C, et al. Sun exposure, vitamin D intake and progression to disability among veterans with progressive multiple sclerosis. Neuroepidemiology. 2011; 37 (1): 52-7.
21. Jones G,. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008; 88 (2): 582S-6S.
22. Smolders J, Menheere P, Thewissen M, Peelen E, Tervaert JW, Hupperts R, et al. Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. J Steroid Biochem Mol Biol. 2010; 121 (1-2): 243-6.
23. Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene). Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009; 41 (7): 824-8.
24. Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010; 68 (2): 193-203.
25. Soilu-Hänninen M, Laaksonen M, Laitinen I, Erälinna JP, Lilius EM, Mononen I,. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008; 79 (2): 152-7.
26. Disanto G, Ramagopalan SV, Para AE, Handunnetthi L,. The emerging role of vitamin D binding protein in multiple sclerosis. J Neurol. 2011; 258 (3): 353-8.
27. Qin Z, Qin Y, Liu S,. Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell Mol Neurobiol. 2009; 29 (2): 203-10.
28. Liu S, Bai S, Qin Z, Yang Y, Cui Y, Qin Y,. Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. J Cell Mol Med. 2009; 13 (8A): 1586-603.
29. Ottervald J, Franzén B, Nilsson K, Andersson LI, Khademi M, Eriksson B, et al. Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers. J Proteomics. 2010; 73 (6): 1117-32.
30. Matsumoto T, Takano T, Yamakido S, Takahashi F, Tsuji N,. Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism. J Steroid Biochem Mol Biol. 2010; 121 (1-2): 261-4.
31. Handunnetthi L, Ramagopalan SV, Ebers GC,. Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology. 2010; 74 (23): 1905-10.